TerrAscend (TSNDF) Amortization of Deferred Charges (2021 - 2026)
TerrAscend's (TSNDF) quarterly Amortization of Deferred Charges came in at $378000.0 in Q1 2026, down 7.35% year-on-year from $408000.0 in Q1 2025, and down 2.33% on a QoQ basis from $387000.0 in Q4 2025.
TerrAscend (TSNDF) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Amortization of Deferred Charges data on file, last reported at $378000.0 in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges fell 7.35% year-over-year to $378000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 19.56% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, down 1.36% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $378000.0, down from $387000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for TSNDF reached as high as $716000.0 in Q1 2024 and fell as low as -$367000.0 in Q4 2023.
- Historically, Amortization of Deferred Charges has averaged $401941.2 across 5 years, with a median of $439000.0 in 2022.
- Across the five-year window, Amortization of Deferred Charges tumbled 178.59% in 2023 and surged 550.82% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $467000.0 in 2022, then tumbled by 178.59% to -$367000.0 in 2023, then soared by 223.71% to $454000.0 in 2024, then fell by 14.76% to $387000.0 in 2025, then declined by 2.33% to $378000.0 in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $378000.0 in Q1 2026, $387000.0 in Q4 2025, and $403000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.12 Bn | 20.96 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | TerrAscend | 166.39 Mn | 165.92 Mn | 34.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 378,000.00 |
| Mar 31, 2026 | 378,000.00 |
| Dec 31, 2025 | 387,000.00 |
| Dec 31, 2025 | 387,000.00 |
| Sep 30, 2025 | 403,000.00 |
| Sep 30, 2025 | 403,000.00 |
| Jun 30, 2025 | 397,000.00 |
| Jun 30, 2025 | 397,000.00 |
| Mar 31, 2025 | 408,000.00 |
| Mar 31, 2025 | 408,000.00 |
| Dec 31, 2024 | 454,000.00 |
| Dec 31, 2024 | 454,000.00 |
| Sep 30, 2024 | 386,000.00 |
| Sep 30, 2024 | 386,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Mar 31, 2024 | 716,000.00 |
| Mar 31, 2024 | 716,000.00 |
| Dec 31, 2023 | -367,000.00 |
| Dec 31, 2023 | -367,000.00 |